The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone

Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors

(2013) Pilar Mur et al.   ACTA NEUROPATHOLOGICA

Predictors of Long-Term Survival in Patients With Glioblastoma Multiforme: Advancements From the Last Quarter Century

(2013) Nauman S. Chaudhry et al.   CANCER INVESTIGATION

Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience

(2013) J. S. Frenel et al.   JOURNAL OF NEURO-ONCOLOGY

Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution

(2013) Sandra H E Boots-Sprenger et al.   MODERN PATHOLOGY

IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival

(2013) S. Leu et al.   NEURO-ONCOLOGY

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

(2013) W. Wick et al.   NEUROLOGY

Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma

(2013) Yongzhi Wang et al.   NEUROSURGICAL REVIEW

Can MGMT promoter methylation status be used as a prognostic and predictive marker for glioblastoma multiforme at the present time?

(2013) R. Fietkau et al.   STRAHLENTHERAPIE UND ONKOLOGIE

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

(2012) Pierre Bady et al.   ACTA NEUROPATHOLOGICA

Relationship between Tumor Enhancement, Edema,IDH1Mutational Status,MGMTPromoter Methylation, and Survival in Glioblastoma

(2012) J.A. Carrillo et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Pathologic Diagnosis of Recurrent Glioblastoma

(2012) Jang-Hee Kim et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Clinical and histological characteristics of recurrent oligodendroglial tumors: comparison between primary and recurrent tumors in 18 cases

(2012) Masayuki Kanamori et al.   Brain Tumor Pathology

The Definition of Primary and Secondary Glioblastoma

(2012) H. Ohgaki et al.   CLINICAL CANCER RESEARCH

Recent advances in the molecular understanding of glioblastoma

(2012) Fonnet E. Bleeker et al.   JOURNAL OF NEURO-ONCOLOGY

The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas

(2012) T. A. Juratli et al.   JOURNAL OF NEURO-ONCOLOGY

Impact of extent of resection for recurrent glioblastoma on overall survival

(2012) Orin Bloch et al.   JOURNAL OF NEUROSURGERY

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

(2012) Annika Malmström et al.   LANCET ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

IDH mutation impairs histone demethylation and results in a block to cell differentiation

(2012) Chao Lu et al.   NATURE

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO)

(2012) Annette Leibetseder et al.   NEURO-ONCOLOGY

IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma

(2011) Qi SongTao et al.   CANCER SCIENCE

A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

(2011) M. J. van den Bent et al.   CLINICAL CANCER RESEARCH

Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas

(2011) Jörg Felsberg et al.   INTERNATIONAL JOURNAL OF CANCER

MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations

(2011) Shani Mulholland et al.   INTERNATIONAL JOURNAL OF CANCER

Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance

(2011) D. Kuhnt et al.   NEURO-ONCOLOGY

The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma

(2010) Fonnet E. Bleeker et al.   ACTA NEUROPATHOLOGICA

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

(2010) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter

(2010) Kazuya Motomura et al.   CANCER

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Segregation of non-p.R132H mutations inIDH1in distinct molecular subtypes of glioma

(2010) Lonneke A.M. Gravendeel et al.   HUMAN MUTATION

Molecular signatures classify astrocytic gliomas byIDH1mutation status

(2010) Grischa Toedt et al.   INTERNATIONAL JOURNAL OF CANCER

Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival

(2010) Christian Ewelt et al.   JOURNAL OF NEURO-ONCOLOGY

The DNA methylome of glioblastoma multiforme

(2010) Ramon Martinez et al.   NEUROBIOLOGY OF DISEASE

Patterns of Care and Survival in a Retrospective Analysis of 1059 Patients With Glioblastoma Multiforme Treated Between 2002 and 2007: A Multicenter Study by the Central Nervous System Study Group of Airo (Italian Association of Radiation Oncology)

(2010) Silvia Scoccianti et al.   NEUROSURGERY

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas

(2009) Takuya Watanabe et al.   AMERICAN JOURNAL OF PATHOLOGY

Robust Detection of EGFR Copy Number Changes and EGFR Variant III: Technical Aspects and Relevance for Glioma Diagnostics

(2009) Judith Jeuken et al.   BRAIN PATHOLOGY

Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology

(2009) L. A.M. Gravendeel et al.   CANCER RESEARCH

IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas

(2009) S. Nobusawa et al.   CLINICAL CANCER RESEARCH

IDH1mutations at residue p.R132 (IDH1R132) occur frequently in high-grade gliomas but not in other solid tumors

(2009) Fonnet E. Bleeker et al.   HUMAN MUTATION

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

(2009) Michael Weller et al.   JOURNAL OF CLINICAL ONCOLOGY

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

(2009) Koichi Ichimura et al.   NEURO-ONCOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Absence of AKT1 Mutations in Glioblastoma

(2009) Fonnet E. Bleeker et al.   PLoS One

Epigenetic mechanisms in glioblastoma multiforme

(2009) Raman P. Nagarajan et al.   SEMINARS IN CANCER BIOLOGY

Analysis of the IDH1 codon 132 mutation in brain tumors

(2008) Jörg Balss et al.   ACTA NEUROPATHOLOGICA

Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age

(2008) Yohan Lee et al.   BMC Medical Genomics

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Promoter Methylation and Polymorphisms of the MGMT Gene in Glioblastomas: A Population-Based Study

(2008) Izabela Zawlik et al.   NEUROEPIDEMIOLOGY

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE